Cannabis Law Report

SEPTEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. Mack, Chairman and CEO of Virpax.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc. 646) 421-9523.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. Additionally, they may help slow the growth of certain types of cancer cells, though further research is needed.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Medicinal Marijuana Association

AUGUST 27, 2019

Extensive research in the United States and England on cannabis in the 1930s came to a halt with the beginning of World War II and did not pick up again afterwards due to the various laws and regulations that classified the plant as a drug.Legal issuescontinued to inhibit serious study until half a century ago, when Prof.

Research and Development 66

Research and Development Clinical Trials Patients Epilepsy 66

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We This product candidate is being funded through a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS).

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 6, 2021

Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. Food and Drug Administration (“FDA”). Forward-Looking Statement.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

– Multiple Contracts Awarded to Support the Development and Manufacturing of Envelta (NES100) – BERWYN, Pa.–(BUSINESS IND-enabling studies for Envelta are being performed under a Cooperative Research and Development Agreement (CRADA) with NCATS entered into by Virpax in August of 2020. “We

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

CannaTech

SEPTEMBER 23, 2019

This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Furthermore, pharmaceutical companies often fund and initiate randomised clinical trials to validate their drugs.

Patients 79

Patients Policy Clinical Trials Research and Development 79

MMJ Recs

DECEMBER 28, 2023

In this article, we’ll talk about a few of the most common conditions for which medical marijuana is prescribed, exploring the growing body of research and real-world experiences that contribute to its acceptance as a viable therapeutic option.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

MMJ Recs

JULY 5, 2024

Understanding THC’s mechanisms and clinical implications is crucial as researchers continue to uncover its therapeutic potential and limitations in medical settings. Neurological Disorders Research suggests THC may benefit neurological conditions such as epilepsy, multiple sclerosis (MS), and Parkinson’s disease.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

MMJ Recs

DECEMBER 17, 2023

Here’s some insight into what the program involves: Intractable Epilepsy Focus: The TCUP is highly focused, primarily catering to individuals diagnosed with one of a specific number of qualifying conditions (more on this below). Current Texas Medical Marijuana Regulations CBD laws in Texas are governed by the Compassionate Use Program.

Law 52

Law Clinical Trials Dispensary Programs 52

Cannabis Law Report

DECEMBER 18, 2019

Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. Both products are proprietary medicinal drugs developed internally through MGC’s research and development divisions.

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

Cannabis Law Report

DECEMBER 23, 2021

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. However, regulations are constantly shifting.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

The Joint Blog

JANUARY 12, 2020

However, researchers warn that not only are not all CBD pet products made equally, but some contain no CBD at all. You’d be astounded by the analysis we’ve seen of products on the shelf with virtually no CBD in them,” said Cornell University veterinary researcher Joseph Wakshlag: He studies therapeutic uses for the compound.

Pets 36

Pets CBD Clinical Trials Research and Development 36

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

SEPTEMBER 22, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. A vast majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

OCTOBER 26, 2021

MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Dr. Chapman Bio.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 1, 2021

(“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that Chairman and CEO Anthony P. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Otherside Farms

APRIL 14, 2020

Research on CBD ( cannabidiol ) shows that it has vast therapeutic properties. The findings were confirmed by similar research conduction in the following year. The findings were confirmed by similar research conduction in the following year. In June of 2019, the FDA in the U.S.

CBD 52

CBD Research and Development Sleep Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-? About MYMD-1.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

JULY 13, 2019

clinical trials have been made by Members of Parliament. But it says one of the barriers to research is that industry is not always prepared to supply products for research trials. Instead, it would be helpful to encourage these companies to develop a greater understanding in the UK.”. CBD Testers.co

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., Moreover, the FDA has also allowed researchers to conduct CBD trials. But things have changed after FDA eased out regulations in 2015 to carry out CBD trials.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Cannabis Law Report

NOVEMBER 24, 2019

Recommendations for research. Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. potential impact on structural and functional brain development. Recommendations. Rationale and impact.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! government classified all cannabis varieties, including hemp, as Schedule I under the Controlled Substances Act (despite decades of agricultural research detailing its differences from marijuana). What makes CBD special? In 1970, the U.S. CBD & Epidiolex.

CBD 100

CBD DEA Research and Development Hemp 100

Alchimia

FEBRUARY 1, 2022

Recent scientific studies have proven that cannabidiol contains the following therapeutic properties: Anticonvulsant : especially suitable to treat Dravet syndrome, a very aggressive type of childhood epilepsy. Neuroprotective : could contribute to the treatment of neurodegenerative diseases such as multiple sclerosis. Drowsiness.

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Cannabis Law Report

SEPTEMBER 1, 2019

In the months that followed, Fitzsimons and Yeend publicly criticised the government for failing to facilitate their plans quickly enough; the government ruled the Holden plant out as a potential site for cannabis cultivation; Australian Cannabis Corporation lost a major research partnership; and the pair had a messy, public falling out.

Clinical Trials 53

Clinical Trials Research and Development Medicine Cultivation 53

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Marijuana law reform advocates and many medical researchers have been fighting to change marijuana’s Schedule I classification for years. Schedule I classification typically pertains to narcotic substances with no medical value.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66